Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia | NEJM – (no positive effect)

In this trial involving hospitalized patients with severe Covid-19 pneumonia, we found no significant difference in clinical status between the tocilizumab group and the placebo group at day 28. No mortality benefit was associated with the use of tocilizumab, although the trial was not powered for this outcome.  Source: Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia | NEJM